原发性胆汁性胆管炎新药在海南博鳌乐城获批

Core Insights - Seladelpar, a drug for primary biliary cholangitis (PBC), has been approved in Hainan Boao Lecheng International Medical Tourism Pilot Zone, marking it as the first potent selective PPARδ agonist approved for this condition globally [1][2] - PBC is an autoimmune liver disease that can lead to severe complications such as liver cirrhosis and liver failure if not treated effectively [1][2] - The approval of Seladelpar represents a significant advancement in treatment options for PBC patients, particularly those who do not respond well to the standard treatment with ursodeoxycholic acid (UDCA) [2] Industry Context - PBC has been included in China's second batch of rare disease catalog, with a reported prevalence of 20.5 per 100,000, predominantly affecting middle-aged women [2] - Approximately 40% of PBC patients do not respond adequately to UDCA, which poses a high risk of disease progression to decompensated cirrhosis and liver failure [2] - The introduction of Seladelpar is expected to address unmet clinical needs and improve both biochemical markers and symptoms such as itching, which affects 70% of patients [2] Regulatory Environment - The Boao Lecheng International Medical Tourism Pilot Zone is recognized as China's only "medical special zone," facilitating the introduction of innovative drugs and therapies [3] - Prior to its approval in Boao, Seladelpar was granted access through a clinical urgent import policy in August 2025, indicating a proactive approach to rare disease treatment in China [3]